[
    "{\"step_by_step_thinking\": \"Based on the information provided in the relevant documents, the use of bexarotene for relapsing-remitting multiple sclerosis is not recommended. Document [0] states that the study assessing the safety and efficacy of bexarotene in promoting remyelination in people with multiple sclerosis showed poor tolerability and a negative primary efficacy outcome. Document [3] also mentions that the clinical trial showed that bexarotene can cause remyelination but will not lead to the drug being used as a therapy due to its risk profile. Therefore, the answer is B. no.\", \"answer_choice\": \"B\"}"
]